

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at [www.tga.gov.au/reporting-problems](http://www.tga.gov.au/reporting-problems).

## **AUSTRALIAN PRODUCT INFORMATION - PIQRAY® (alpelisib) tablets**

### **1. NAME OF THE MEDICINE**

Alpelisib

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

#### **Active substance**

All PIQRAY tablets contain alpelisib.

#### PIQRAY 50 mg tablet

Each tablet contains 50 mg of alpelisib.

#### PIQRAY 150 mg tablet

Each tablet contains 150 mg of alpelisib.

#### PIQRAY 200 mg tablet

Each tablet contains 200 mg of alpelisib.

#### **Excipients**

For the list of excipients, see section 6.1 List of Excipients.

### **3. PHARMACEUTICAL FORM**

#### **Film coated tablets**

#### PIQRAY 50 mg tablet

Light pink, unscored, round and curved with bevelled edges, imprinted with “L7” on one side and “NVR” on the other side.

#### PIQRAY 150 mg tablet

Pale red, unscored, ovaloid and curved with bevelled edges, imprinted with “UL7” on one side and “NVR” on the other side.

#### PIQRAY 200 mg tablet

Light red, unscored, ovaloid and curved with bevelled edges, imprinted with “YL7” on one side and “NVR” on the other side.

### **4. CLINICAL PARTICULARS**

#### **4.1 Therapeutic indications**

PIQRAY in combination with fulvestrant, is indicated for the treatment of postmenopausal women, and men, with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer with a PIK3CA mutation as detected by a validated test following progression on or after an endocrine-based regimen.

#### **4.2 Dose and method of administration**

Treatment with PIQRAY should be initiated by a physician experienced in the use of anticancer therapies.

Patients with HR positive, HER2 negative advanced breast cancer should be selected for treatment

with PIQRAY, based on the presence of a PIK3CA mutation in tumour or plasma specimens, using a validated test. If a mutation is not detected in a plasma specimen, test tumour tissue if available.

The safety and efficacy of alpelisib in combination with a GnRH agonist in pre- or peri-menopausal women has not been established.

There was no treatment benefit demonstrated in patients without PIK3CA mutations, in the phase III clinical study (see section 5.1 Pharmacodynamic properties).

### Adult Dose

#### *Recommended Dosage*

The recommended dose of PIQRAY is 300 mg (two 150 mg film-coated tablets) taken orally, once daily. PIQRAY should be taken immediately following food, at approximately the same time each day (see section 5.1 Pharmacodynamic properties and section 4.5 Interactions with other medicines and other forms of interactions). The maximum recommended daily dose of PIQRAY is 300 mg. If patient vomits after taking the PIQRAY dose, the patient should not take an additional dose on that day, and should resume the usual dosing schedule the next day, at the usual time.

When co-administered with PIQRAY, the recommended dose of fulvestrant is 500 mg administered intramuscularly on days 1, 15 and, 29, and once monthly thereafter. Please refer to the full product information of fulvestrant.

Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs. Dosing modifications may be necessary to improve tolerability.

#### *Missed dose*

If a dose of PIQRAY is missed, it can be taken immediately following food and within 9 hours after the time it is usually administered. After more than 9 hours, the missed dose should be skipped for that day. On the next day, PIQRAY should be taken at its usual time.

#### *Dose modifications*

The recommended daily dose of PIQRAY is 300 mg. Management of severe or intolerable adverse drug reactions may require temporary dosing interruption, reduction, and/or discontinuation of PIQRAY. If dosing reduction is required, the dosing reduction guidelines for adverse drug reactions (ADRs) are listed in Table 1. A maximum of 2 dosing reductions are recommended, after which the patient should be discontinued from treatment with PIQRAY. Dosing reduction should be based on worst preceding toxicity.

**Table 1 Recommended Dosing reduction guidelines for adverse drug reactions for PIQRAY<sup>1</sup>**

PIQRAY dose level	Dose and schedule	Number and strength of tablets
Starting dose	300 mg/day continuously	2 x 150 mg tablets
First dose reduction	250 mg/day continuously	1 x 200 mg tablet and 1 x 50 mg tablet
Second dose reduction	200 mg/day continuously	1 x 200 mg tablet

<sup>1</sup>Only one dose reduction is permitted for pancreatitis.

Tables 2, 3, 4 and 5 summarise recommendations for dosing interruption, reduction or discontinuation of PIQRAY in the management of specific ADRs. Clinical judgment of the treating physician, including confirmation of laboratory values if deemed necessary, should guide the management plan of each patient based on the individual benefit/risk assessment for treatment with PIQRAY.

### Hyperglycaemia

Consultation with a Healthcare Professional (HCP) with experience in the management of hyperglycemia should be considered and lifestyle changes as per local guidelines, including exercise and dietary advice should be recommended/reinforced (e.g. small frequent meals, low carbohydrate, high fiber, low processed food intake, three macronutrient balanced meals and 2 optional small snacks rather than one large meal).

Premedication with metformin may decrease the incidence and severity of hyperglycemia when metformin is initiated 7 days prior to the start of treatment with PIQRAY and metformin dose titrated to the maximum tolerated dose. Patient risk factors for hyperglycaemia, gastrointestinal tolerability and the clinical situation should be considered before initiating metformin premedication. See section 4.4 Special warnings and precautions for use and section 4.8 Adverse effects (undesirable effects).

In patients with risk factors for hyperglycaemia, monitor fasting glucose more closely and as clinically indicated (see section 4.4 Special warnings and precautions for use).

**Table 2 Dosing Modification and Management for Hyperglycaemia<sup>1</sup>**

<b>Fasting Glucose (FG)<sup>1</sup></b>	<b>Recommendation</b>
<b>Dose modifications and management should only be based on fasting glucose (plasma/blood) values.</b>	
> ULN - 160 mg/dL or > ULN - 8.9 mmol/L	No PIQRAY dose adjustment required. Initiate or intensify oral anti-diabetic treatment <sup>2</sup> .
>160 - 250 mg/dL or > 8.9 - 13.9 mmol/L.	No PIQRAY dose adjustment required. Initiate or intensify oral anti-diabetic treatment <sup>2</sup> .  If FG does not decrease to ≤160 mg/dL or 8.9 mmol/L within 21 days with appropriate oral anti-diabetic treatment <sup>2,3</sup> , reduce PIQRAY dose by 1 dose level, and follow FG value specific recommendations.
> 250 - 500 mg/dL or > 13.9 - 27.8 mmol/L	Interrupt PIQRAY.  Initiate or intensify oral anti-diabetic treatment <sup>3</sup> and consider additional anti-diabetic medications (such as insulin <sup>3</sup> ) for 1-2 days until hyperglycaemia resolves, as clinically indicated.  Administer intravenous hydration and consider appropriate treatment (e.g. intervention for electrolyte/ketoacidosis/hyperosmolar disturbances).  If FG decreases to ≤160 mg/dL or 8.9 mmol/L within 3 to 5 days under appropriate anti-diabetic treatment, resume PIQRAY at next lower dose level.  If FG does not decrease to ≤160 mg/dL or 8.9 mmol/L within 3 to 5 days under appropriate anti-diabetic treatment, consultation with a physician with expertise in the treatment of hyperglycemia is recommended.  If FG does not decrease to ≤160 mg/dL or 8.9 mmol/L within 21 days following appropriate anti-diabetic treatment <sup>2,3</sup> , permanently discontinue PIQRAY treatment.
> 500 mg/dL or > 27.8 mmol/L	Interrupt PIQRAY  Initiate or intensify appropriate anti-diabetic treatment <sup>2,3</sup> (administer intravenous hydration and consider appropriate treatment (e.g. intervention for electrolyte/ketoacidosis/hyperosmolar disturbances)), re-check within 24 hours and as clinically indicated.  If FG decreases to (≤ 500 mg/dL) or (≤ 27.8 mmol/L), then follow FG value specific recommendations for (<500 mg/dL) or (<27.8 mmol/L).

	If FG is confirmed at > 500 mg/dL or (> 27.8 mmol/L), permanently discontinue PIQRAY treatment.
--	---

<sup>1</sup>Fasting Glucose levels reflect hyperglycaemia grading according to CTCAE Version 4.03. CTCAE=Common Terminology Criteria for Adverse Events.

<sup>2</sup> Applicable anti-diabetic medications, like metformin, SGLT2 inhibitors or insulin sensitisers (such as thiazolidinediones or dipeptidyl peptidase-4 inhibitors), should be initiated and respective prescribing information should be reviewed for dosing and dose titration recommendations, including local diabetic treatment guidelines. Metformin was recommended in the phase III clinical study with the following guidance: Metformin 500 mg once daily should be initiated. Based on tolerability, metformin dose may be increased to 500 mg twice daily, followed by 500 mg with breakfast, and 1000 mg with dinner, followed by further increase to 1000 mg twice daily if needed (see section 4.4 Special warnings and precautions for use).

<sup>3</sup>As recommended in the phase III clinical study, insulin may be used for 1-2 days until hyperglycemia resolves. However, this may not be necessary in the majority of alpelisib-induced hyperglycemia, given the short half-life of alpelisib and the expectation of glucose levels normalising after interruption of PIQRAY.

## Rash

Oral antihistamine administration may be considered prophylactically, at the time of initiation of treatment with PIQRAY. Based on the severity of rash, PIQRAY may require dose interruption, reduction, or discontinuation as described in Table 3 (see section 4.8 Adverse effects (undesirable effects)).

**Table 3 Dosing Modification and Management for Rash<sup>1</sup>**

Grade <sup>1</sup>	Recommendation
All Grades	Consultation with dermatologist should always be considered
Grade 1 (<10% body surface area (BSA) with active skin toxicity)	No PIQRAY dose adjustment required. Initiate topical corticosteroid treatment. Consider adding oral antihistamine treatment to manage symptoms. If active rash is not improved within 28 days of appropriate treatment, add a low dose systemic corticosteroid.
Grade 2 (10-30% BSA with active skin toxicity)	No PIQRAY dose adjustment required. Initiate or intensify topical corticosteroid and oral antihistamine treatment. Consider low dose systemic corticosteroid treatment. If rash improves to Grade ≤1 within 10 days, systemic corticosteroid may be discontinued.
Grade 3 (e.g.: severe rash not responsive to medical management). (>30% BSA with active skin toxicity)	Interrupt PIQRAY until rash improves to Grade ≤ 1. Initiate or intensify topical/systemic corticosteroid and anti-histamine treatment. Once rash improves to Grade ≤ 1, resume PIQRAY at next lower dose level
Grade 4 (e.g.: severe bullous, blistering, or exfoliating skin conditions). (any % BSA associated with extensive superinfection, with intravenous antibiotics indicated; life-threatening consequences)	Permanently discontinue PIQRAY.

<sup>1</sup>Grading according to CTCAE Version 5.0

## Diarrhoea

Please refer to Table 4 for dosing modifications and management guidelines.

**Table 4 Dosing Modification and Management for Diarrhoea or colitis**

Grade <sup>1</sup>	Recommendation
Grade 1	No PIQRAY dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated.
Grade 2	Interrupt PIQRAY dose until improvement to Grade $\leq 1$ , then resume PIQRAY at same dose level.  For recurrent Grade $\geq 2$ , interrupt PIQRAY dose until improvement to Grade $\leq 1$ , then resume PIQRAY at the next lower dose level.  Initiate or intensify appropriate medical therapy and monitor as clinically indicated <sup>2</sup> .
Grade 3	Interrupt PIQRAY dose until improvement to Grade $\leq 1$ , then resume PIQRAY at the next lower dose level.  Initiate or intensify appropriate medical therapy and monitor as clinically indicated <sup>2, 3</sup> .
Grade 4	Permanently discontinue PIQRAY <sup>3</sup> .
<sup>1</sup> Grading according to CTCAE Version 5.0. <sup>2</sup> For Grade 2 and 3 colitis consider additional treatment, such as steroids. <sup>3</sup> For Grade 3 and 4 diarrhoea, patients should additionally be managed according to local standard of care, including electrolyte monitoring, administration of antiemetics and antidiarrhoeal medicinal products and/or fluid replacement and electrolyte supplements, as clinically indicated.	

#### Other toxicities

Please refer to Table 5 for the dosing modification and management for other toxicities (excluding hyperglycaemia and rash).

**Table 5 Dosing Modification and Management for other toxicities (excluding hyperglycaemia, rash and diarrhoea or colitis)<sup>1</sup>**

Grade <sup>1</sup>	Recommendation
Grade 1	No PIQRAY dose adjustment required. Initiate appropriate medical therapy and monitor as clinically indicated <sup>2,3</sup>
Grade 2	
Grade 3	Interrupt PIQRAY dose until improvement to Grade $\leq 1$ , then resume PIQRAY at the next lower dose level <sup>2</sup> .
Grade 4	Permanently discontinue PIQRAY.

<sup>1</sup> Grading according to CTCAE Version 5.0

<sup>2</sup> For Grade 2 and 3 pancreatitis, interrupt PIQRAY dose until improvement to Grade  $\leq 1$  and resume at next lower dose level. Only one dose reduction is permitted. If toxicity recurs, permanently discontinue PIQRAY treatment.

<sup>3</sup> For Grade 2 total bilirubin elevation, interrupt PIQRAY dose until improvement to Grade  $\leq 1$  and resume at the same dose if improved in  $\leq 14$  days or resume at the next lower dose level if improved in  $> 14$  days.

Grade <sup>1</sup>	Recommendation
--------------------	----------------

### Fulvestrant

For dose modification guidelines in the event of toxicity or for any other relevant safety information, refer to the fulvestrant product information.

### Special populations

#### *Renal impairment*

Based on population pharmacokinetic analysis, no dose adjustment is necessary in patients with mild or moderate renal impairment (see section 5.2 Pharmacokinetic properties). Caution should be used in patients with severe renal impairment as there is no experience with PIQRAY in this population (see section 5.2 Pharmacokinetic properties).

#### *Hepatic impairment*

Based on a hepatic impairment study in non-cancer subjects with impaired hepatic function, no dose adjustment is necessary in patients with mild, moderate, and severe hepatic impairment (Child-Pugh class A, B or C, respectively) (see section 5.2 Pharmacokinetic properties).

Refer to the product information of fulvestrant for dose modifications related to hepatic impairment.

#### *Paediatric use*

The safety and efficacy of PIQRAY in paediatric patients have not been established.

#### *Use in the elderly*

No dosage regimen adjustment is required in patients 65 years or above (see section 5.2 Pharmacokinetic properties).

### Administration

PIQRAY tablets should be swallowed whole (tablets should not be chewed, crushed or split prior to swallowing). Tablets that are broken, cracked, or otherwise not intact should not be ingested.

## **4.3 Contraindications**

PIQRAY is contraindicated in patients with hypersensitivity to the active substance or any of the excipients (see Section 6.1 List of excipients).

## **4.4 Special warnings and precautions for use**

### Hypersensitivity (including anaphylactic reaction)

Serious hypersensitivity reactions (including anaphylactic reaction and anaphylactic shock), manifested by symptoms including, but not limited to, dyspnoea, flushing, rash, fever, or tachycardia were reported in patients treated with PIQRAY in clinical studies (see section 4.8 Adverse effects (undesirable effects)). Angioedema has been reported in the post marketing setting in patients treated with PIQRAY (see section 4.8, adverse effects (undesirable effects)). PIQRAY should be permanently discontinued and should not be re-introduced in patients with serious hypersensitivity reactions. Appropriate treatment should be promptly initiated.

### Severe cutaneous reactions

Severe cutaneous reactions have been reported with PIQRAY. In the Phase III clinical study, Stevens-Johnson syndrome (SJS) and erythema multiforme (EM) were reported in 1 (0.4%) and 3 (1.1%) patients, respectively. Drug reaction with eosinophilia and systemic symptoms (DRESS)

has been reported in the post marketing setting (see section 4.8 Adverse effects (undesirable effects)). PIQRAY treatment should not be initiated in patients with history of severe cutaneous reactions.

Patients should be advised of the signs and symptoms of severe cutaneous reactions (e.g. a prodrome of fever, flu-like symptoms, mucosal lesions, or progressive skin rash). If signs or symptoms of severe cutaneous reactions are present, PIQRAY should be interrupted until the etiology of the reaction has been determined. A consultation with dermatologist is recommended. If a severe cutaneous reaction is confirmed, PIQRAY should be permanently discontinued. PIQRAY should not be reintroduced in patients who have experienced previous severe cutaneous reactions. If a severe cutaneous reaction is not confirmed, PIQRAY may require treatment interruption, dose reduction, or treatment discontinuation as described in Table 3 Dose modification and management for rash (see section 4.2 Dose and method of administration).

### Hyperglycaemia

Severe hyperglycaemia, in some cases associated with hyperglycaemic hyperosmolar nonketotic syndrome (HHNKS) or ketoacidosis, has been observed in patients treated with PIQRAY. Some cases of ketoacidosis with fatal outcome have been reported in the post marketing setting.

Hyperglycaemia events were reported in 67.3% (191/284) of patients treated with PIQRAY in the phase III clinical study. Grade 2 (FPG > 8.9 – 13.9 mmol/L), 3 (FPG > 13.9 – 27.8 mmol/L) or 4 (FPG > 27.8 mmol/L) hyperglycaemia events were reported in 15.8%, 34.5% and 4.6% of patients, respectively, in phase III clinical study. Ketoacidosis was reported in 1.1% of patients treated with PIQRAY in the phase III clinical study. In the phase III clinical study, patients with a history of diabetes mellitus intensified anti-diabetic medication(s) while on treatment with PIQRAY; therefore these patients require monitoring and possibly intensified anti-diabetic treatment. Patients with poor glycaemic control may be at a higher risk of developing severe hyperglycaemia and associated complications. Patients with risk factors for hyperglycaemia such as obesity (BMI  $\geq 30$ ), elevated FPG or HbA1c at or above the upper limit of normal, or age  $\geq 75$  are at a higher risk of developing severe hyperglycaemia. The schedule for monitoring fasting glucose is presented in Table 6.

Patients should be advised of the signs and symptoms of hyperglycaemia (e.g. excessive thirst, urinating more often than usual or higher amount of urine than usual, and increased appetite with weight loss).

The safety of PIQRAY in patients with Type 1 and uncontrolled Type 2 diabetes has not been established as these patients were excluded from the Phase III clinical study.

**Table 6 Schedule of fasting glucose monitoring**

	Recommended schedule for the monitoring of fasting glucose and HbA1c levels in all patients treated with PIQRAY	Recommended schedule of monitoring of fasting glucose and HbA1c levels in patients with diabetes, pre-diabetes, BMI ≥30 or age ≥75 years treated with PIQRAY
At screening, before initiating treatment with PIQRAY	Test for fasting plasma glucose (FPG), HbA1c, and optimise the patient's level of blood glucose	
After initiating treatment with PIQRAY	Monitor/self-monitor fasting glucose at least once every week for the first 2 weeks, then at least once every 4 weeks, and as clinically indicated, according to the instructions of a healthcare professional*	Monitor/self-monitor fasting glucose more frequently for the first few weeks of treatment. Continue to monitor fasting glucose as frequently as needed to manage hyperglycaemia according to the instructions of a healthcare professional*.
	HbA1c should be monitored every 3 months.	
If hyperglycaemia develops after initiating treatment with PIQRAY	Monitor fasting glucose regularly, as per local standard of care and at least until fasting glucose decreases to normal levels.	
	During treatment with antidiabetic medication, continue monitoring fasting glucose at least once a week for 8 weeks, followed by once every 2 weeks, and monitor fasting glucose according to the instructions of a healthcare professional with expertise in the treatment of hyperglycaemia.	

*\* All glucose monitoring should be performed at the physician's discretion as clinically indicated.*

In the phase III clinical study, in patients with hyperglycaemia, 166/191 (86.9%) were managed with anti-diabetic medication and 145/191 (75.9%) reported use of metformin as single agent or in combination with other anti-diabetic medication. The maximum dose of metformin recommended in phase III clinical study was 2000 mg per day.

In patients with hyperglycaemia of at least Grade 2 (FPG  $>8.9$  mmol/L), median time to improvement by at least 1 Grade of the first event was 8 days (95% CI of 8 to 10 days). In all patients with elevated FPG, who continued fulvestrant treatment after discontinuing PIQRAY (n=61), 85.2% (n=52) of patients returned to Grade 0.



Premedication with metformin may decrease the incidence and severity of hyperglycaemia when metformin is initiated 7 days prior to the start of treatment with PIQRAY, but increases the incidence of nausea and vomiting and the incidence and severity of diarrhoea. See section 4.2 Dose and method of administration and section 4.8 Adverse effects (undesirable effects).

Based on the severity of the hyperglycaemia, PIQRAY may require dose interruption, reduction, or discontinuation as described in Table 2 Dose Modification and Management for hyperglycaemia (see section 4.2 Dose and method of administration).

#### Pneumonitis

Pneumonitis including serious cases of pneumonitis/acute interstitial lung disease have been reported in PIQRAY treated patients in clinical studies. Patients should be advised to promptly report any new or worsening respiratory symptoms. In patients who have new or worsening respiratory symptoms or are suspected to have developed pneumonitis, PIQRAY treatment should be interrupted immediately, and the patient should be evaluated for pneumonitis. A diagnosis of non-infectious pneumonitis should be considered in patients presenting with non-specific respiratory signs and symptoms such as hypoxia, cough, dyspnoea, or interstitial infiltrates on radiologic exams and in whom infectious, neoplastic, and other causes have been excluded by means of appropriate investigations. PIQRAY should be permanently discontinued in all patients with confirmed pneumonitis.

#### Diarrhoea or colitis

Severe diarrhoea and clinical consequences, such as dehydration and acute kidney injury and hypovolaemic shock, have been reported during treatment with PIQRAY in clinical studies (see section 4.8 adverse effects, undesirable effects). In the phase III clinical study, diarrhoea (all grades) was reported in 59.9% of patients. Grade 2 diarrhoea was reported in 20.4% and grade 3 was in 7.4% of patients. There were no cases of Grade 4 diarrhoea reported. Among patients with Grade 2 or 3 diarrhoea, median time to onset was 54 days (range: 1 to 1731 days).

Colitis has been reported in the post marketing setting in patients treated with PIQRAY (see section 4.8, adverse effects (undesirable effects)).

In the phase III clinical study, dose reductions of PIQRAY were required in 6.3% (18/284) of patients and 2.8% (8/284) of patients permanently discontinued PIQRAY due to diarrhoea.

Patients should be monitored for diarrhoea and additional symptoms of colitis, such as abdominal pain and mucus or blood in stool. Based on the severity of the diarrhoea or colitis, PIQRAY may require dose interruption, reduction, or discontinuation as described in Table 4 (see section 4.2 Dose and method of administration).

Patients should be advised to notify their healthcare provider if diarrhoea or additional symptoms of colitis occur while taking PIQRAY. Patients should be managed according to local standard of care medical management, including electrolyte monitoring, administration of anti-emetics and anti-diarrhoeal medications and/or fluid replacement and electrolyte supplements, as clinically indicated.

In a case of colitis, additional treatment, such as steroids, may be considered as clinically indicated.

#### Use in hepatic impairment

See Section 4.2 (Dose and method of administration – special populations) and Section 5.2 (Pharmacokinetic properties)

#### Use in renal impairment

See Section 4.2 (Dose and method of administration – special populations) and Section 5.2 (Pharmacokinetic properties)

#### Use in the elderly

See Section 4.2 (Dose and method of administration – special populations) and Section 5.2 (Pharmacokinetic properties)

#### Paediatric use

See Section 4.2 (Dose and method of administration – special populations) and Section 5.2 (Pharmacokinetic properties)

#### Effects on laboratory tests

Refer to Table 8.

### **4.5 Interactions with other medicines and other forms of interactions**

The elimination of alpelisib is majorly driven by non-hepatic hydrolysis, mediated by multiple enzymes (esterases, amidases, choline esterase) and to a lesser degree, CYP3A4 mediated metabolism (hydroxylation). The contribution of hepatobiliary export or intestinal secretion via breast cancer resistance protein (BCRP) in human is considered to be low.

#### Medicinal products that may increase alpelisib plasma concentrations

##### *BCRP inhibitors*

Alpelisib is a sensitive substrate for BCRP *in vitro*, predominantly expressed in the liver, intestine, and at blood-brain barrier. Absorption of alpelisib will not be affected by BCRP inhibition due to saturation of the transporter in the intestine. However, due to the involvement of BCRP in the hepatobiliary export and intestinal secretion of alpelisib, caution is advised when co-administering PIQRAY with a BCRP inhibitor (e.g. eltrombopag, lapatinib, pantoprazole), as inhibition of BCRP in the liver and in the intestine after absorption may lead to an increase in systemic exposure of PIQRAY.

#### Medicinal products that may decrease alpelisib plasma concentrations

##### *CYP3A4 inducers*

Administration of 600 mg once daily rifampin, a strong CYP3A4 inducer, for 7 days, before co-administration with a single oral 300 mg alpelisib dose on Day 8, decreased alpelisib C<sub>max</sub> by 38% and AUC by 57% in healthy adults (N = 25). Administration of 600 mg once daily rifampin for 15 days, co-administered with daily 300 mg alpelisib starting from Day 8 to Day 15 decreased the steady state alpelisib C<sub>max</sub> by 59% and AUC by 74%.

Co-administration with a strong CYP3A4 inducer decreases alpelisib area under the curve (AUC) (see section 5.2, Pharmacokinetic properties), which may reduce alpelisib efficacy. Co-administration of alpelisib with strong CYP3A4 inducers (e.g., apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's wort) should be avoided and selection of an alternative concomitant medicinal product, with no or minimal potential to induce CYP3A4, should be considered (see section 5.1 Pharmacodynamic properties).

#### Medicinal products whose plasma concentrations may be altered by alpelisib

##### *CYP3A4, CYP2C8, CYP2C9, CYP2C19 and CYP2B6 substrates*

*In vitro*, alpelisib is a time-dependent inhibitor and an inducer of CYP3A4. No dose adjustment is required when co-administering PIQRAY with CYP3A4 substrates (e.g. everolimus, midazolam),

CYP2C8 substrates (e.g. repaglinide), CYP2C9 substrates (e.g. warfarin) and CYP2C19 substrates (e.g. omeprazole).

In a drug-drug interaction study of healthy subjects, repeated doses of alpelisib 300 mg was co-administered with a single-dose cocktail of sensitive substrates of CYP3A4 (midazolam), CYP2C8 (repaglinide), CYP2C9 (warfarin), CYP2C19 (omeprazole) and CYP2B6 (bupropion). 76.5% of patients were white, and the majority of subjects were intermediate or normal metabolisers for CYP2C9 and CYP2C19. No clinically significant pharmacokinetic interactions were found. The data from CYP2B6 substrate (bupropion) should be interpreted with caution due to the small sample size. S-warfarin exposure increased on average by 34% and 19% for AUC<sub>inf</sub> and C<sub>max</sub> respectively, compared to administration with S-warfarin alone, which indicates that alpelisib is a mild inhibitor of CYP2C9.

In a drug-drug interaction study in patients with advanced solid tumours, co-administration of alpelisib with everolimus, a sensitive CYP3A4 substrate and a P-gp substrate, showed no clinically significant pharmacokinetic interactions (decrease in AUC by 11.2%). No change in everolimus exposure was observed at alpelisib doses ranging from 250 to 300 mg.

#### Drug-food interactions

In healthy subjects, co-administration of alpelisib with food resulted in an increased AUC of alpelisib by 77% (see section 4.2 Dose and method of administration and section 5.2 Pharmacokinetic properties). Therefore, PIQRAY should be taken immediately after food, at approximately same time each day (see section 4.2 Dose and method of administration).

#### Hormonal contraceptives

It is currently unknown whether alpelisib may reduce the effectiveness of systemically acting hormonal contraceptives.

#### *Transporter-based interaction*

Alpelisib showed weak *in vitro* inhibition towards the efflux transporters P-gp, BCRP, and BSEP, solute carrier transporters at the liver inlet (OATP1B1, OATP1B3, and OCT1) and solute carrier transporters in the kidney (OCT2, MATE1, and MATE2K). As unbound systemic steady state concentrations at the therapeutic dose are significantly lower than the experimentally determined unbound inhibition constants or IC<sub>50</sub>, the inhibition will not translate into clinical significance. However, given the relatively high intestinal and hepatic inlet concentrations of alpelisib, clinically relevant inhibition of oral absorption of P-gp substrates and hepatic uptake of OCT1, OATP1B1 and OAT1B3 substrates may occur. Both alpelisib and the major metabolite, BZG791 inhibited the renal uptake transporter OAT3 (K<sub>i</sub> 29.4 and 1.38 µM, respectively) *in vitro*, and thus alpelisib might increase plasma concentrations of drugs that are predominantly excreted by this transporter. As an *in vitro* inhibitor of OATP1B1 (IC<sub>50</sub> 20.9 µM) alpelisib might also increase plasma concentrations of drugs that are OATP1B1 substrates and predominantly cleared by hepatic metabolism.

#### *Fulvestrant*

Data from a clinical study in patients with breast cancer indicated no effect of fulvestrant on alpelisib exposure (and *vice versa*) following co-administration of the drugs.

## **4.6 Fertility, pregnancy, and lactation**

#### Effects on fertility

There are no clinical data available on the effect of PIQRAY on fertility. Based on findings in animals, PIQRAY may impair fertility in males and females of reproductive potential.

In repeated-dose toxicity studies up to 13 weeks duration in rats, adverse effects were observed in reproductive organs of females (vaginal epithelial atrophy, vaginal atrophy and oestrus cycle variations) at doses >2 mg/kg/day (resulting in subclinical exposures) and males (decreased secretion in prostate and seminal vesicle) at doses >10 mg/kg/day (resulting in subclinical exposure).

Prostate glandular atrophy was observed in dogs administered alpelisib at 15 mg/kg/day at 2.3 times the exposure in humans, at the highest recommended human dose of 300 mg based on AUC). In general, the observed effects were reversible or showed a trend towards reversibility after a 4-8 weeks recovery period.

Alpelisib affected male reproductive organs and female fertility in rat fertility and early embryonic development studies. In two fertility studies, male rats were treated for 10 weeks prior to mating (mated with untreated females) and females for 4 weeks prior to mating (mated with untreated males). In females, at doses of 20 mg/kg/day 1.8 times the exposure (based on AUC) in humans at the recommended human dose of 300 mg), increased pre- and post-implantation losses leading to reduced numbers of implantation sites and live embryos. Female fertility was unaffected at 10 mg/kg/day (resulting in subclinical exposures). In males, at doses of  $\geq 10$  mg/kg/day (exposures approximately equivalent to the clinical AUC), accessory glands weights (seminal vesicles, prostate) were reduced and correlated microscopically with atrophy and/or reduced secretion in prostate and seminal vesicles, respectively. Male fertility parameters were unaffected at doses up to 20 mg/kg/day (1.3 times the exposures in patients at the maximum recommended human dose of 300 mg, based on AUC).

#### Use in Pregnancy (Category D)

Based on animal data and its mechanism of action, PIQRAY can cause fetal harm when administered to a pregnant woman.

There are no adequate and well-controlled studies in pregnant women. Embryo-fetal development studies in rats and rabbits have demonstrated that oral administration of alpelisib during organogenesis induced embryo-lethality, fetotoxicity, and teratogenicity. Increased incidences of post-implantation loss, reduced fetal weights, and increased incidences of fetal abnormalities were observed at 10 mg/kg/day in rats and 15 mg/kg/day in rabbits with systemic exposures 0.8 (rat) and 5 times (rabbit) the exposure in humans at the highest recommended dose of 300 mg/day based on AUC.

PIQRAY should not be used during pregnancy unless the benefits to the mother outweighs the risk to the fetus. If PIQRAY is used during pregnancy, the patient should be advised of the potential risk to the fetus.

#### *Contraception*

A negative pregnancy status for females of reproductive potential should be verified prior to starting treatment with PIQRAY.

Females of reproductive potential should be advised that animal studies and the mechanism of action have shown that alpelisib can be harmful to the developing fetus. Sexually active females of reproductive potential should use effective contraception (methods that result in less than 1% pregnancy rates) when using PIQRAY during treatment and for at least 4 days after stopping treatment with alpelisib. It is currently unknown whether alpelisib may reduce the effectiveness of systemically acting hormonal contraceptives.

Male patients with sexual partners who are pregnant, possibly pregnant, or who could become pregnant should use condoms during sexual intercourse while taking PIQRAY and for at least 4 days after stopping treatment with PIQRAY.

#### Use in Lactation

It is not known if alpelisib is transferred into human or animal milk after administration of PIQRAY. There are no data on the effects of alpelisib on the breastfed child or the effects of alpelisib on milk production.

Because of the potential for serious adverse drug reactions in the breastfed child from PIQRAY, it is recommended that women should not breastfeed during treatment and for at least 4 days after the last dose of PIQRAY.

#### 4.7 Effects on ability to drive and use machines

PIQRAY has minor influence on the ability to drive and use machines. Patients should be advised to be cautious when driving or using machines in case they experience fatigue during treatment with PIQRAY (see section 4.8 Adverse effects (undesirable effects)).

#### 4.8 Adverse effects (undesirable effects)

##### Summary of the safety profile

The overall safety evaluation of PIQRAY is based on data from the phase III clinical study of 572 patients (571 post-menopausal women and 1 male) who were randomised in a 1:1 ratio to receive PIQRAY plus fulvestrant or placebo plus fulvestrant; 284 of whom received PIQRAY at the recommended starting dose of 300 mg dose in combination with fulvestrant, using the proposed treatment regimen.

The median duration of exposure to PIQRAY plus fulvestrant was 8.2 months with 59.2% patients exposed for >6 months.

PIQRAY dose reductions due to adverse events (AEs), regardless of causality occurred in 59.5% (n=169) of patients receiving PIQRAY plus fulvestrant and in 5.2% (n=15) of patients receiving placebo plus fulvestrant. Permanent discontinuations of PIQRAY due to adverse events were reported in 26.1% (n=74) of patients receiving PIQRAY plus fulvestrant. Permanent discontinuations of placebo due to adverse events were reported in 5.6% (n=16) of patients receiving placebo plus fulvestrant. The most common AEs leading to treatment discontinuation of both PIQRAY and/or fulvestrant were hyperglycaemia (6.3%), rash (3.2%), diarrhoea (2.8%), and fatigue (2.1%).

On-treatment deaths, regardless of causality, were reported in 9 patients (3.2%) treated with PIQRAY plus fulvestrant vs. 12 patients (4.2%) treated with placebo plus fulvestrant. In PIQRAY plus fulvestrant treated patients, disease progression (7 patients, 2.5%) was the most frequent cause of death; the others were one each for cardio-respiratory arrest and second primary malignancy, neither of which were considered related to treatment with PIQRAY.

The most common adverse drug reactions (ADRs) in PIQRAY plus fulvestrant treated patients (reported at a frequency >20% and for which the frequency for PIQRAY plus fulvestrant exceeds the frequency for placebo plus fulvestrant) were hyperglycaemia, diarrhoea, rash, nausea, fatigue and asthenia, decreased appetite, stomatitis, vomiting, weight decreased and alopecia.

The most common Grade 3/4 ADRs (reported at a frequency >2% in PIQRAY plus fulvestrant arm and for which the frequency for PIQRAY plus fulvestrant exceeds the frequency for placebo plus fulvestrant) were hyperglycaemia, rash, diarrhoea, weight decreased, fatigue, anaemia, hypertension, lipase increased, hypokalaemia, gamma-glutamyltransferase increased, alanine aminotransferase increased, lymphopenia, nausea, osteonecrosis of jaw, stomatitis, mucosal inflammation and acute kidney injury.

##### Tabulated summary of adverse drug reactions from clinical studies

ADRs from the phase III clinical study (Table 7) are listed by MedDRA system organ class. Within each system organ class, the ADRs are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, ADRs are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each ADR is based on the following convention (CIOMS III):

Very common  $\geq 1/10$   
Common  $\geq 1/100$  to  $< 1/10$

Uncommon  $\geq 1/1,000$  to  $< 1/100$   
Rare  $\geq 1/10,000$  to  $< 1/1,000$   
Very rare  $< 1/10,000$ .

**Table 7 Adverse drug reactions observed in the phase III clinical study**

Adverse drug reactions	PIQRAY + Fulvestrant N= 284 n (%) All Grades	Placebo + Fulvestrant N= 287 n (%) All Grades	PIQRAY + Fulvestrant N= 284 n (%) Grades 3/4	Placebo + Fulvestrant N=287 n (%) Grades 3/4	Frequency category for PIQRAY + Fulvestrant  All Grades
<b>Blood and lymphatic system disorders</b>					
Anaemia	37 (13.0)	21 (7.3)	15 (5.3)	4 (1.4)	Very common
Lymphopenia	16 (5.6)	5 (1.7)	9 (3.2)	3 (1.0)	Common
Thrombocytopenia	7 (2.5)	5 (1.7)	2 (0.7)	2 (0.7)	Common
<b>Eye disorders</b>					
Vision blurred	15 (5.3)	2 (0.7)	1 (0.4)	0	Common
Dry eye	10 (3.5)	1 (0.3)	0	0	Common
<b>Gastrointestinal disorders</b>					
Diarrhoea	170 (59.9)	48 (16.7)	21 (7.4)	2 (0.7)	Very common
Nausea	133 (46.8)	65 (22.6)	8 (2.8)	1 (0.3)	Very common
Stomatitis <sup>1</sup>	87 (30.6)	20 (7.0)	7 (2.5)	0	Very common
Vomiting	84 (29.6)	29 (10.1)	2 (0.7)	1 (0.3)	Very common
Abdominal pain	53 (18.7)	34 (11.8)	4 (1.4)	4 (1.4)	Very common
Dyspepsia	33 (11.6)	17 (5.9)	0	0	Very common
Toothache	13 (4.6)	7 (2.4)	1 (0.4)	0	Common
Gingivitis	11 (3.9)	2 (0.7)	1 (0.4)	0	Common
Gingival pain	11 (3.9)	0	0	0	Common
Cheilitis	8 (2.8)	0	0	0	Common
Pancreatitis	1 (0.4)	0	1 (0.4)	0	Uncommon
<b>General disorders and administrative site conditions</b>					
Fatigue <sup>2</sup>	125 (44.0)	86 (30.0)	16 (5.6)	3 (1.0)	Very common
Mucosal inflammation	56 (19.7)	4 (1.4)	6 (2.1)	0	Very common
Peripheral oedema	48 (16.9)	16 (5.6)	0	1 (0.3)	Very common
Pyrexia	48 (16.9)	16 (5.6)	2 (0.7)	1 (0.3)	Very common
Mucosal dryness <sup>3</sup>	37 (13.0)	13 (4.5)	1 (0.4)	0	Very common
Oedema <sup>4</sup>	20 (7.0)	1 (0.3)	0	0	Common
<b>Immune system disorders</b>					
Hypersensitivity <sup>5</sup>	12 (4.2)	0	2 (0.7)	0	Common
<b>Infections and infestations</b>					
Urinary tract infection <sup>6</sup>	29 (10.2)	16 (5.6)	2 (0.7)	3 (1.0)	Very common
<b>Investigations</b>					
Weight decreased	80 (28.2)	7 (2.4)	17 (6.0)	0	Very common

<b>Adverse drug reactions</b>	<b>PIQRAY + Fulvestrant N= 284 n (%) All Grades</b>	<b>Placebo + Fulvestrant N= 287 n (%) All Grades</b>	<b>PIQRAY + Fulvestrant N= 284 n (%) Grades 3/4</b>	<b>Placebo + Fulvestrant N=287 n (%) Grades 3/4</b>	<b>Frequency category for PIQRAY + Fulvestrant  All Grades</b>
Blood creatinine increased	36 (12.7)	4 (1.4)	5 (1.8)	0	Very common
Gamma-glutamyltransferase increased	28 (9.9)	23 (8.0)	12 (4.2)	17 (5.9)	Common
Alanine aminotransferase increased	28 (9.9)	18 (6.3)	10 (3.5)	7 (2.4)	Common
Lipase increased	22 (7.7)	12 (4.2)	15 (5.3)	11 (3.8)	Common
Glycosylated haemoglobin increased	9 (3.2)	0	0	0	Common
<b>Metabolism and nutrition disorders</b>					
Hyperglycaemia	188 (66.2)	28 (9.8)	107 (37.7)	3 (1.0)	Very common
Decreased appetite	105 (37.0)	30 (10.5)	3 (1.1)	1 (0.3)	Very common
Hypokalemia	30 (10.6)	5 (1.7)	14 (4.9)	1 (0.3)	Very common
Hypocalcaemia	12 (4.2)	5 (1.7)	2 (0.7)	1 (0.3)	Common
Dehydration	10 (3.5)	4 (1.4)	1 (0.4)	3 (1.0)	Common
Ketoacidosis <sup>7</sup>	3 (1.1)	0	3 (1.1)	0	Common
<b>Musculoskeletal and connective tissue disorders</b>					
Muscle spasms	23 (8.1)	12 (4.2)	0	1 (0.3)	Common
Myalgia	20 (7.0)	9 (3.1)	1 (0.4)	0	Common
Osteonecrosis of jaw	16 (5.6)	5 (1.7)	8 (2.8)	3 (1.0)	Common
<b>Nervous system disorders</b>					
Headache	55 (19.4)	38 (13.2)	2 (0.7)	0	Very common
Dysgeusia <sup>8</sup>	44 (15.5)	8 (2.8)	1 (0.4)	0	Very common
<b>Psychiatric disorders</b>					
Insomnia	22 (7.7)	12 (4.2)	0	0	Common
<b>Renal and Urinary disorders</b>					
Acute kidney injury	17 (6.0)	2 (0.7)	6 (2.1)	1 (0.3)	Common
<b>Respiratory, thoracic and mediastinal disorders</b>					
Pneumonitis <sup>9</sup>	5 (1.8)	1 (0.3)	1 (0.4)	1 (0.3)	Common
<b>Skin and subcutaneous tissue disorders</b>					
Rash <sup>10</sup>	148 (52.1)	24 (8.4)	55 (19.4)	1 (0.3)	Very common
Alopecia	58 (20.4)	7 (2.4)	0	0	Very common
Pruritus	54 (19.0)	19 (6.6)	2 (0.7)	0	Very common
Dry skin <sup>11</sup>	53 (18.7)	11 (3.8)	1 (0.4)	0	Very common
Erythema <sup>12</sup>	19 (6.7)	2 (0.7)	2 (0.7)	0	Common
Dermatitis <sup>13</sup>	10 (3.5)	3 (1.0)	2 (0.7)	0	Common
Palmar-plantar erythrodysesthesia syndrome	5 (1.8)	1 (0.3)	0	0	Common
Erythema multiforme	3 (1.1)	0	2 (0.7)	0	Common
Stevens-Johnson syndrome	1 (0.4)	0	1 (0.4)	0	Uncommon

<b>Adverse drug reactions</b>	<b>PIQRAY + Fulvestrant N= 284 n (%) All Grades</b>	<b>Placebo + Fulvestrant N= 287 n (%) All Grades</b>	<b>PIQRAY + Fulvestrant N= 284 n (%) Grades 3/4</b>	<b>Placebo + Fulvestrant N=287 n (%) Grades 3/4</b>	<b>Frequency category for PIQRAY + Fulvestrant  All Grades</b>
<b>Vascular disorders</b>					
Hypertension	30 (10.6)	17 (5.9)	15 (5.3)	11 (3.8)	Very common
Lymphoedema	17 (6.0)	6 (2.1)	0	0	Common

<sup>1</sup> Stomatitis: also includes aphthous ulcer and mouth ulceration

<sup>2</sup> Fatigue: also includes asthenia

<sup>3</sup> Mucosal dryness: also includes dry mouth, vulvovaginal dryness

<sup>4</sup> Oedema: also includes face swelling, face oedema, eyelid oedema

<sup>5</sup> Hypersensitivity: also includes allergic dermatitis

<sup>6</sup> Urinary tract infection: also includes single case of urosepsis

<sup>7</sup> Ketoacidosis: also includes diabetic ketoacidosis (See Section 4.4, Special warnings and precautions for use)

<sup>8</sup> Dysgeusia : also includes ageusia, hypogeusia

<sup>9</sup> Pneumonitis: also includes interstitial lung disease

<sup>10</sup> Rash: also includes rash maculo-papular, rash macular, rash generalised, rash-papular, rash pruritic

<sup>11</sup> Dry skin: also includes skin fissures, xerosis, xeroderma

<sup>12</sup> Erythema: also includes erythema generalised

<sup>13</sup> Dermatitis: also includes dermatitis acneiform

**Table 8 Laboratory abnormalities observed in the phase III study**

<b>Laboratory abnormalities</b>	<b>PIQRAY + Fulvestrant N= 284 n (%) All Grades</b>	<b>Placebo + Fulvestrant N= 287 n (%) All Grades</b>	<b>PIQRAY + Fulvestrant N= 284 n (%) Grades 3/4</b>	<b>Placebo + Fulvestrant N=287 n (%) Grades 3/4</b>	<b>Frequency category for PIQRAY + Fulvestrant All Grades</b>
<b>Hematological parameters</b>					
Lymphocyte count decreased	158 (55.6)	117 (40.8)	28 (9.9)	13 (4.5)	Very common
Hemoglobin decreased	129 (45.4)	86 (30.0)	15 (5.3)	5 (1.7)	Very common
Activated partial thromboplastin time increased	68 (23.9)	53 (18.5)	2 (0.7)	2 (0.7)	Very common
Platelet count decreased	42 (14.8)	21 (7.3)	3 (1.1)	2 (0.7)	Very common
<b>Biochemical parameters</b>					
Glucose plasma increased	225 (79.2)	100 (34.8)	112 (39.4)	5 (1.7)	Very common
Creatinine increased	193 (68.0)	77 (26.8)	9 (3.2)	2 (0.7)	Very common
Gamma-glutamyl transferase increased	154 (54.2)	133 (46.3)	35 (12.3)	32 (11.1)	Very common
Alanine aminotransferase increased	128 (45.1)	101 (35.2)	13 (4.6)	7 (2.4)	Very common
Lipase increased	123 (43.3)	76 (26.5)	20 (7.0)	18 (6.3)	Very common
Calcium corrected decreased	79 (27.8)	57 (19.9)	6 (2.1)	5 (1.7)	Very common
Glucose plasma decreased	78 (27.5)	41 (14.3)	1 (0.4)	0	Very common
Albumin decreased	44 (15.5)	22 (7.7)	1 (0.4)	0	Very common
Potassium decreased	43 (15.1)	8 (2.8)	19 (6.7)	2 (0.7)	Very common



Laboratory abnormalities	PIQRAY + Fulvestrant N= 284 n (%) All Grades	Placebo + Fulvestrant N= 287 n (%) All Grades	PIQRAY + Fulvestrant N= 284 n (%) Grades 3/4	Placebo + Fulvestrant N=287 n (%) Grades 3/4	Frequency category for PIQRAY + Fulvestrant All Grades
Magnesium decreased	36 (12.7)	13 (4.5)	1 (0.4)	0	Very common

*Adverse drug reactions from spontaneous reports and literature cases (frequency not known)*

The following adverse drug reactions have been derived from post-marketing experience with PIQRAY via spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorised as not known.

**Table 9 Adverse drug reactions from spontaneous reports and literature cases (frequency not known)**

---

<b>Eye disorders</b>
Uveitis
<b>Gastrointestinal disorders</b>
Colitis
<b>Metabolism and nutrition disorders</b>
Hyperglycaemic hyperosmolar nonketotic syndrome (HHNKS)
<b>Skin and subcutaneous tissue disorders</b>
Angioedema
Drug reaction with eosinophilia and systemic symptoms (DRESS)

---

*Description of selected ADRs and treatment recommendations, where applicable*

*Hyperglycaemia*

In the phase III clinical study, hyperglycaemia events (all grades) were reported in 191/284 (67.3%) of patients. An event of hyperglycaemia resolved to  $\leq$  Grade 1 (FPG < 160 mg/dL (< 8.9 mmol/L)) in 174 (91.1%) of the 191 patients. Dose interruptions and adjustments due to hyperglycaemic events were reported in 26.8% (76/284) and 29.2% (83/284) of patients, respectively, in the PIQRAY plus fulvestrant arm. Hyperglycaemic events leading to permanent discontinuation of PIQRAY and/or fulvestrant were reported in 20/284 (7.0%) patients. Based on baseline FPG and HbA1c values, 56% of patients were considered pre-diabetic (FPG 100 to 125 mg/dL (5.6 to 6.9 mmol/L) and/or HbA1c 5.7-6.4%) and 4.2% of patients were considered diabetic (FPG  $\geq$  126 mg/dL ( $\geq$  7.0 mmol/L) and/or HbA1c  $\geq$  6.5%). There were no patients with type 1 diabetes mellitus based on reported medical history in the phase III clinical study. Among those pre-diabetic patients at baseline, 75.5% experienced hyperglycaemia (any Grade) when treated with PIQRAY. Among the patients who had Grade  $\geq$  2 (FPG > 160 mg/dL (> 8.9 mmol/L)) hyperglycaemia, the median time to first occurrence of Grade  $\geq$  2 (FPG > 160 mg/dL (> 8.9 mmol/L)) hyperglycaemia was 15 days (range: 5 days to 1458 days) (based on laboratory findings). The median duration of Grade 2 or higher (FPG > 160 mg/dL (> 8.9 mmol/L)) hyperglycaemia (based on laboratory findings) was 10 days (95% CI: 8 to 13 days).

*Metformin Premedication for Hyperglycaemia*

The use of PIQRAY and endocrine therapy with metformin premedication was evaluated in METALLICA, an open-label, single-arm, two-cohort study in patients with HR-positive, HER2-negative advanced breast cancer harbouring PIK3CA mutation(s). Most patients (93%) received fulvestrant as endocrine therapy during the study. Cohort A enrolled patients with normal glycaemic status (FPG < 100 mg/dl [< 5.6 mmol/L] and HbA1c < 5.7%) and Cohort B enrolled patients with impaired glycaemic status (FPG 100–140 mg/dL [5.6–7.8 mmol/L] or HbA1c 5.7%–6.4%). The overall median age was 55 years.

Metformin was administered beginning 7 days prior to treatment with PIQRAY. On Day 1 to Day 3, metformin 500 mg twice daily was administered orally and then increased up to 1,000 mg twice daily based on tolerability. All patients received a glucometer to self-monitor blood glucose in addition to laboratory-based monitoring. Concomitant use of systemic glucocorticoids occurred for 37% of patients in METALLICA (in SOLAR-1, this occurred for 43% of patients with a PIK3CA mutation randomised to receive alpelisib + fulvestrant).

Hyperglycaemia adverse reactions occurred in 33% (16/48) and 70% (14/20 patients) in Cohort A and Cohort B, respectively. Grade 3-4 hyperglycaemia occurred in 2.1% (1/48) of patients in Cohort A and 15% (3/20) of patients in Cohort B. The incidence of nausea, vomiting, and diarrhoea adverse reactions, including Grade 3 diarrhoea, increased with metformin premedication. For more information on diarrhoea in patients treated with PIQRAY, see PI Section 4.4: Special warnings and precautions for use - Diarrhoea or colitis.

Serious adverse reactions occurred in 22% of patients in the METALLICA study and serious adverse reactions  $\geq$  2% included diarrhoea (3%), rash (3%) and vomiting (3%).

The most common Grade 3-4 adverse reactions ( $\geq$  5%) were rash (16%), diarrhoea (13%), and hyperglycaemia (6%).

Permanent discontinuation of PIQRAY due to adverse reactions in the METALLICA study occurred in 19% of patients, and dose modification or interruption of PIQRAY due to adverse reactions occurred in 56% of patients, of which 28% were dose reductions.

The most common adverse reactions ( $\geq$  30%) in the METALLICA study were diarrhoea (68%), nausea (68%), fatigue (46%), hyperglycaemia (44%), rash (38%), and vomiting (34%).

See PI section 4.2: Dose and method of administration, Hyperglycaemia, for considerations relating to the use of metformin premedication.

### *Rash*

In the phase III clinical study, rash events (including rash maculo-papular, rash macular, rash generalised, rash papular, rash pruritic, dermatitis and dermatitis acneiform) were reported in 154/284 (54.2%) patients. Each patient may have experienced more than one event or type of rash. Overall, 161 rash events were reported. Rash may be accompanied by pruritus and dry skin in some cases. Rash was predominantly mild or moderate (Grade 1 or 2) and responsive to therapy. Maximum Grade 2 and 3 rash events were reported in 13.7% and 20.1% of patients, respectively. There were no Grade 4 cases of rash reported. Among the patients with Grade 2 or 3 rash, the median time to first onset of Grade 2 or 3 rash was 12 days (range: 2 days to 220 days). Dose interruptions and dose adjustments due to rash were reported in 21.8% and 9.2% of patients, respectively, in the PIQRAY plus fulvestrant arm.

Topical corticosteroid treatment should be initiated at the first signs of rash and systemic corticosteroids should be considered for moderate to severe rashes. Additionally, antihistamines are recommended to manage symptoms of rash. In the Phase III study, among the patients who developed a rash and used anti-rash medication, 84.6% (115/136) reported use of at least one topical corticosteroid and 76.5% (104/136) of at least one oral antihistamine. Systemic corticosteroids were administered for rash events in 18.3% (52/284) of patients. Of the patients who received systemic corticosteroids, 73.1% (38/52) received only oral corticosteroids for rash. At least one event of rash resolved in the majority of the patients, 146 out of 154 patients (94.8%). Discontinuation of PIQRAY and/or fulvestrant treatment due to rash events occurred in 12 patients (4.2%).

A subgroup of 89 patients received anti rash treatment, including anti-histamines, prior to onset of rash. In these patients, rash was reported less frequently than in the overall population, for all Grades rash (25.8% vs 54.2%), Grade 3 rash (11.2% vs 20.1%) and rash leading to permanent discontinuation of PIQRAY (3.4% vs 4.2%). Accordingly, antihistamines may be initiated prophylactically, at the time of initiation of treatment with PIQRAY. Based on the severity of rash,

PIQRAY may require dose interruption, reduction, or discontinuation as described in Table 3 Dose Modification and Management for rash (see section 4.2 Dose and method of administration).

#### *GI toxicity (nausea, diarrhoea, vomiting)*

In the phase III study, diarrhoea, nausea and vomiting were reported in 170/284 (59.9%), 133/284 (46.8%) and 84/284 (29.6%) of the patients, respectively, and led to permanent discontinuation of PIQRAY and/or fulvestrant in 8/284 (2.8%), 5/284 (1.8%) and 4/284 (1.4%) of the patients, respectively (see Table 7).

Anti-emetics (e.g. ondansetron) and anti-diarrhoeal medications (e.g. loperamide) were used in 29/153 (19.0%) and 111/170 (65.3%) of patients to manage symptoms.

#### *Osteonecrosis of the jaw (ONJ)*

In the phase III clinical study, ONJ was reported in 6.0% of patients (17/284) in the PIQRAY plus fulvestrant arm compared to 1.7% of patients (5/287) in the placebo plus fulvestrant arm. All patients experiencing ONJ were also exposed to prior or concomitant bisphosphonates (e.g. zoledronic acid) or RANK-ligand inhibitors (e.g. denosumab). Therefore, in patients receiving PIQRAY and bisphosphonates or RANK-ligand inhibitors, an increased risk of development of ONJ cannot be excluded.

#### Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at [www.tga.gov.au/reporting-problems](http://www.tga.gov.au/reporting-problems).

## **4.9 Overdose**

### Symptoms

There is limited experience of overdose with PIQRAY in clinical studies. In the clinical studies, PIQRAY was administered at doses up to 450 mg once daily.

In cases where accidental over-dosage of PIQRAY was reported in the clinical studies, the adverse events associated with the overdose were consistent with the known safety profile of PIQRAY and included hyperglycaemia, nausea, asthenia, and rash.

### Treatment

General symptomatic and supportive measures should be initiated in all cases of over dosage where necessary. There is no known antidote for PIQRAY.

For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

## **5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents

Anatomical Therapeutic Chemical (ATC Code): L01EM03.

### **5.1 Pharmacodynamic properties**

#### Mechanism of action

Alpelisib is a class I phosphatidylinositol3kinase (PI3K) inhibitor with higher activity against PI3K $\alpha$  than other members of class I PI3K. Class I PI3K lipid kinases are key components of the PI3K/AKT/mTOR (mammalian target of rapamycin) signalling pathway.

Gain-of-function mutations in the gene encoding the catalytic  $\alpha$ -subunit of PI3K (PIK3CA) lead to activation of PI3K $\alpha$  manifested by increased lipid kinase activity, growth-factor independent activation of AKT-signalling, cellular transformation and the generation of tumours in preclinical models.

*In vitro*, alpelisib treatment inhibited the phosphorylation of PI3K downstream targets AKT as well as its various downstream effectors in breast cancer cells and showed activity towards cell lines harbouring a PIK3CA mutation.

*In vivo*, alpelisib showed good tolerability as well as dose- and time-dependent inhibition of the PI3K/AKT pathway and dose-dependent tumour growth inhibition in relevant tumour xenograft models, including models of breast cancer.

PI3K inhibition by alpelisib treatment has been shown to induce an increase in ER transcription in breast cancer cells, therefore, sensitising these cells to estrogen receptor (ER) inhibition by fulvestrant treatment. Combination of alpelisib and fulvestrant demonstrated increased anti-tumour activity than either treatment alone in xenograft models derived from ER+, PIK3CA mutated breast cancer cell lines (MCF-7 and KPL1).

#### Pharmacodynamic effects

In biochemical assays, alpelisib inhibited wild type PIK3 $\alpha$  and its 2 most common somatic mutations (H1047R, E545K) ( $IC_{50}$  ~5 nmol/L) more potently than the PI3K $\delta$  ( $IC_{50}$  = 60 nmol/L) and PI3K $\gamma$  ( $IC_{50}$  = 560 nmol/L) isoforms and showed significantly reduced activity against PI3K $\beta$  ( $IC_{50}$  = 1156 nmol/L).

The potency and selectivity of alpelisib was confirmed at the cellular level in mechanistic and relevant tumour cell lines.

#### Cardiac electrophysiology

Serial, triplicate ECGs were collected following a single dose and at steady state to evaluate the effect of alpelisib on the QTcF interval in patients with advanced cancer. A pharmacokinetic-pharmacodynamic analysis included a total of 134 patients treated with alpelisib at doses ranging from 30 to 450 mg.

The analysis demonstrates the absence of a clinically significant QTcF prolongation at the recommended 300 mg dose with or without fulvestrant. The estimated mean change from baseline in QTcF was <10 ms (7.2 ms; 90% CI: 5.62, 8.83) at the observed geometric-mean  $C_{max}$  at steady-state (2900 ng/mL) following single agent administration at the recommended 300 mg dose.

#### Clinical Trials

##### *Placebo-controlled study C2301 – SOLAR-1*

PIQRAY was evaluated in a pivotal phase III, randomised, double-blind, placebo-controlled study of PIQRAY in combination with fulvestrant in men and postmenopausal women with HR+, HER2-locally advanced breast cancer whose disease had progressed or recurred on or after an aromatase inhibitor-based treatment (with or without CDK4/6 combination).

A total of 572 patients were enrolled into two cohorts, cohort with PIK3CA mutation or cohort without PIK3CA mutation breast cancer. PIK3CA mutation status was determined by clinical trial assays. There were 341 patients enrolled by tumour tissue in the cohort with a PIK3CA mutation and 231 enrolled in the cohort without a PIK3CA mutation. Of the 341 patients in the cohort with a PIK3CA mutation, 98% (333/341) patients had one or more PIK3CA mutations confirmed in tumour tissue using the QIAGEN therascreen® PIK3CA RGQ PCR Kit. The remaining 2% (8/341) of patients did not have their PIK3CA mutations confirmed in tumour tissue. Out of the 333 patients

with PIK3CA mutations confirmed in tumour tissue, 6% (21/333) patients had no plasma specimen available for testing with the QIAGEN therascreen® PIK3CA RGQ PCR Kit. Of the remaining 312 patients with PIK3CA mutations confirmed in tumour tissue, 56% (175/312) patients had PIK3CA mutations identified in plasma specimen, and 44% (137/312) patients did not have PIK3CA mutations identified in plasma specimen.

Patients were randomised to receive either PIQRAY 300 mg plus fulvestrant or placebo plus fulvestrant in a 1:1 ratio. Randomisation was stratified by presence of lung and/or liver metastasis and previous treatment with CDK4/6 inhibitor(s).

Within the cohort with a PIK3CA mutation, 169 patients were randomised to receive PIQRAY in combination with fulvestrant and 172 patients were randomised to placebo in combination with fulvestrant. Within this cohort, 170 (49.9%) patients had liver/lung metastases and 20 (5.9%) patients had received prior CDK4/6 inhibitor treatment.

Within the cohort without PIK3CA mutation, 115 patients were randomised to receive PIQRAY in combination with fulvestrant and 116 were randomised to receive placebo in combination with fulvestrant. 112 (48.5%) patients had liver/lung metastases and 15 (6.5%) patients had prior CDK4/6 inhibitor treatment.

In the cohort with PIK3CA mutation, 97.7% of patients received prior hormonal therapy and 47.8% of patients had the last setting as metastatic and 51.9% of patients whose last setting was adjuvant therapy. Overall, 85.6% of the patients were considered to have endocrine resistant disease; primary endocrine resistance was observed in 13.2% and secondary endocrine resistance in 72.4% of patients.

In both cohorts with or without PIK3CA mutation, demographics and baseline disease characteristics, ECOG performance status, tumour burden, and prior antineoplastic therapy were well balanced between the study arms.

During the randomised treatment phase, PIQRAY 300 mg or PIQRAY matching placebo was administered orally once daily on a continuous basis. Fulvestrant 500 mg was administered intramuscularly on Cycle 1 Day 1 and 15 and then at Day 1 of a 28-day cycle during treatment phase (administration +/- 3 days).

Patients were not allowed to cross over from placebo to PIQRAY during the study or after disease progression.

The primary end point for the study was progression-free survival (PFS) using Response Evaluation Criteria in Solid Tumours (RECIST v1.1), based on the investigator assessment in patients with a PIK3CA mutation. The key secondary end point was overall survival (OS) for patients with a PIK3CA mutation.

Other secondary endpoints included PFS for patients without a PIK3CA mutation, OS for patients without PIK3CA mutation, as well as overall response rate (ORR) by PIK3CA mutation cohort.

#### Cohort with PIK3CA mutation

Patients enrolled with a PIK3CA mutation had a median age of 63 years (range 25 to 92). 44.9% patients were 65 years of age or older and < 85 years. The patients included were White (66.3%), Asian (21.7%), Black or African American (1.2%).

#### Primary Analysis

The study met its primary objective at the final PFS analysis (data cut-off date 12-Jun-2018) demonstrating a statistically significant improvement in PFS by investigator assessment in the PIK3CA mutant cohort for patients receiving PIQRAY plus fulvestrant, compared to patients receiving placebo plus fulvestrant (hazard ratio [HR] = 0.65 with 95% CI: 0.50, 0.85, one sided

stratified log-rank test  $p=0.00065$ ), with an estimated 35% risk reduction of disease progression or death in favour of treatment with PIQRAY plus fulvestrant. The median PFS was prolonged by 5.3 months, from 5.7 months (95% CI: 3.7, 7.4) in the placebo plus fulvestrant arm to 11 months (95% CI: 7.5, 14.5) in the PIQRAY plus fulvestrant arm.

Primary PFS results were supported by consistent results from a blinded independent review committee (BIRC) assessment in this cohort.

PFS Efficacy results from the study are summarised in Table 10 and Figure 1.

**Table 10 Study C2301- Primary efficacy analysis – Summary of results based on RECIST criteria (FAS, cohort with PIK3CA mutation)**


	<b>PIQRAY + Fulvestrant (n=169)</b>	<b>Placebo + Fulvestrant (n=172)</b>	<b>Hazard ratio (HR)</b>	<b>p-value<sup>a</sup></b>
<b>Median progression free survival (PFS<sup>a</sup>) (months, 95% CI)</b>				
<i>Investigator radiological assessment</i>				
PIK3CA mutant cohort (N=341)	11.0 7.5-14.5	5.7 3.7-7.4	0.65 0.50-0.85	0.00065

*Data cut-off date: 12JUN2018*

*CI=confidence interval; N=number of patients;*

*<sup>a</sup>p-value is obtained from the one-sided stratified log-rank test.*

**Figure 1 Study C2301 primary efficacy analysis - Kaplan-Meier plot of Progression Free Survival in cohort with PIK3CA mutation per local investigator assessment FAS, PIK3CA mutant cohort). Data cut-off date: 12-Jun-2018.**



Time (Months)	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32
Alpelisib + Fulv	169	145	123	97	85	75	62	50	39	30	17	14	5	3	1	1	0
Placebo + Fulv	172	120	89	80	67	58	48	37	29	20	14	9	3	2	0	0	0

Treatment with the combination of PIQRAY plus fulvestrant was associated with improvements in ORR relative to placebo + fulvestrant. The ORR was 26.6% (95% CI: 20.1, 34.0) in the PIQRAY plus fulvestrant arm and 12.8% (95% CI: 8.2, 18.7) in the placebo plus fulvestrant arm.

For patients with measurable disease at baseline, the ORR was 35.7% (95% CI: 27.4, 44.7) in the PIQRAY plus fulvestrant arm and 16.2% (95% CI: 10.4, 23.5) in the placebo plus fulvestrant arm.


### Final OS Analysis

The final Overall Survival (OS) analysis was conducted using a data cut-off date of 23-Apr-2020 and PFS was re-run using this data cut. With a median duration from randomisation to data cut-off of approximately 42 months, the PFS benefit was sustained and consistent with results from the final PFS analysis.

At the final OS analysis, the study did not meet its key secondary objective. As of the data cut-off date of 23-Apr-2020, a total of 87 (51.5%) deaths were reported in the PIQRAY plus fulvestrant arm and 94 (54.7%) in the placebo plus fulvestrant arm. The HR was 0.86 (95% CI: 0.64, 1.15;  $p = 0.15$ , one-sided) and the pre-specified O'Brien-Fleming efficacy boundary of  $p \leq 0.0161$  was not crossed. Median OS was prolonged by 7.9 months, from 31.4 months (95% CI: 26.8, 41.3) in

the placebo plus fulvestrant arm to 39.3 months (95% CI: 34.1, 44.9) in the PIQRAY plus fulvestrant arm. See Figure 2 for details.

**Figure 2 Study C2301 key secondary analysis - Kaplan-Meier plot of OS (FAS, PIK3CA mutant cohort) with cut-off date of 23-Apr-2020.**



OS subgroup analyses by randomisation stratification factors demonstrated a homogeneous and generally consistent treatment effect per investigator assessment. In patients with prior CDK4/6i treatment (n=20), the median OS in the alpelisib plus fulvestrant arm was 29.8 months (95% CI: 6.7, 38.2) compared to 12.9 months (95% CI: 2.5, 34.6) in the placebo plus fulvestrant arm (HR=0.67; 95% CI: 0.21, 2.18).

#### Cohort without PIK3CA mutation

The proof of concept criteria to conclude a treatment benefit with PIQRAY and fulvestrant with respect to PFS in patients in the PIK3CA non-mutant cohort were not met (HR = 0.85; 95% CI: 0.58, 1.25) (see section 4.2 Dose and method of administration).

## 5.2 Pharmacokinetic properties

The pharmacokinetics (PK) of alpelisib were investigated in patients under an oral dosing regimen ranging from 30 to 450 mg daily. Healthy subjects received single oral doses ranging from 300 mg to 400 mg. The PK was mostly comparable in both oncology patients and healthy subjects.

### Absorption

Following oral administration of alpelisib, median time to reach peak plasma concentration (T<sub>max</sub>) ranged between 2.0 to 4.0 hours, independent of dose, time, or regimen. Based on absorption modelling bioavailability was estimated to be very high (> 99%) under fed conditions but lower under fasted conditions (~68.7% at a 300 mg dose). Steady-state plasma levels of alpelisib after daily dosing can be expected to be reached on day 3, following onset of therapy in most patients.



### *Food effect*

Alpelisib absorption is affected by food. In healthy volunteers after a single 300 mg oral dose of alpelisib, compared to the fasted state, a high-fat high-calorie (HFHC) meal (985 calories with 58.1 g of fat) increased AUC<sub>inf</sub> by 73% and C<sub>max</sub> by 84%, and a low-fat low-calorie (LFLC) meal (334 calories with 8.7 g of fat) increased AUC<sub>inf</sub> by 77% and C<sub>max</sub> by 145%. No significant difference was found for AUC<sub>inf</sub> between LFLC and HFHC with a geometric mean ratio of 0.978 [CI: 0.876, 1.09] showing that neither fat content nor overall caloric intake has a considerable impact on absorption. The increase in gastrointestinal solubility by bile, secreted in response to food intake, is considered to be the driver of the food effect. Hence, PIQRAY should be taken immediately after food, at approximately same time each day.

### *Acid reducing agents*

The co-administration of the H<sub>2</sub> receptor antagonist ranitidine in combination with a single 300 mg oral dose of alpelisib slightly reduced the bioavailability of alpelisib and decreased overall exposure of alpelisib. In the presence of a LFLC meal, AUC<sub>inf</sub> was decreased on average by 21% and C<sub>max</sub> by 36% with ranitidine. In the absence of food, the effect was more pronounced with a 30% decrease in AUC<sub>inf</sub> and a 51% decrease in C<sub>max</sub> with ranitidine compared to the fasted state without co-administration of ranitidine. PIQRAY can be co-administered with drugs that are acid-reducing agents, if PIQRAY is taken immediately after food. Population pharmacokinetic analysis showed no significant effect on the PK of PIQRAY by co-administration of acid reducing agents including proton pump inhibitors, H<sub>2</sub> receptor antagonists and antacids.

### Distribution

Alpelisib moderately binds to protein with a free fraction of 10.8% regardless of concentration. Alpelisib was equally distributed between red blood cells and plasma with a mean *in vivo* blood-to-plasma ratio of 1.03. The volume of distribution of alpelisib at steady-state (V<sub>ss</sub>/F) is estimated at 114 L (intersubject CV% 49%).

### Metabolism

*In vitro* studies demonstrated that formation of the hydrolysis metabolite BZG791 by chemical and enzymatic amide hydrolysis was a major metabolic pathway, followed by CYP3A4 mediated hydroxylation. Alpelisib hydrolysis occurs systemically by both chemical decomposition and enzymatic hydrolysis via ubiquitously expressed, high-capacity enzymes (esterases, amidases, and choline esterase) not limited to the liver. CYP3A4-mediated metabolites and glucuronides amounted to ~15% of the dose and BZG791 accounted for ~40-45% of the dose. The rest of the dose, which was found as unchanged alpelisib in urine and faeces, was either excreted as alpelisib or non-absorbed.

### Excretion

Alpelisib exhibits low clearance with 9.2 L/hr (CV% 21%) based on population PK analysis under fed conditions. The population derived half-life, independent of dose and time, was 8 to 9 hours at steady state of 300mg, once daily.

In human mass-balance study, after oral administration, alpelisib and its metabolites were primarily found in the faeces (81.0%), as alpelisib or metabolised as BZG791. Excretion in the urine is minor (13.5%), with 2% of unchanged alpelisib. Following single oral dose of [<sup>14</sup>C] alpelisib, 94.5% of the total administered radioactive dose was recovered within 8 days.

### Linearity/non-linearity

The pharmacokinetics were found to be linear with respect to dose and time under fed conditions between 30 and 450 mg. After multiple doses, Alpelisib exposure (AUC) at steady-state is only

slightly higher than that of a single dose with an average accumulation of 1.3 to 1.5 with a daily dosing regimen.

### Special Patient Populations

#### *Renal Impairment*

No dose adjustment is necessary in patients with mild or moderate renal impairment. Patients with severe renal impairment have not been studied and caution should be used. Based on a population pharmacokinetic analysis that included 117 patients with normal renal function (eGFR  $\geq 90$  mL/min/1.73 m<sup>2</sup>) / (CL<sub>cr</sub>  $\geq 90$  mL/min), 108 patients with mild renal impairment (eGFR 60 to  $< 90$  mL/min/1.73 m<sup>2</sup>) / (CL<sub>cr</sub> 60 to  $< 90$  mL/min), and 45 patients with moderate renal impairment (eGFR 30 to  $< 60$  mL/min/1.73 m<sup>2</sup>), mild and moderate renal impairment had no effect on the exposure of alpelisib (see section 4.2 Dose and method of administration).

#### *Hepatic Impairment*

No dose adjustment is necessary in patients with mild, moderate or severe hepatic impairment (Child-Pugh A, B and C).

Based on a pharmacokinetic trial in patients with hepatic impairment, moderate and severe hepatic impairment had negligible effect on the exposure of alpelisib (see section 4.2 Dosage and administration). The mean exposure for alpelisib was increased by 1.26-fold in patients with severe (GMR: 1.00 for C<sub>max</sub>; 1.26 for AUC<sub>last</sub> / AUC<sub>inf</sub>) hepatic impairment.

Based on a population pharmacokinetic analysis that included 230 patients with normal hepatic function, 45 patients with mild hepatic impairment and no patients with moderate hepatic impairment, further supporting the findings from the dedicated hepatic impairment study, mild and moderate hepatic impairment had no effect on the exposure of alpelisib, (see section 4.2 Dosage and administration).

#### *Paediatric use*

The pharmacokinetics of PIQRAY in paediatric patients have not been established.

#### *Use in the elderly*

Of 284 patients who received PIQRAY in the phase III study (in PIQRAY plus fulvestrant arm), 117 patients were  $\geq 65$  years of age and 34 patients were  $\geq 75$  years of age. No overall differences in safety or effectiveness of PIQRAY were observed between these patients and younger patients (see section 4.2 Dosage and administration).

#### *Age, body weight, and gender*

The population PK analysis showed that there are no clinically relevant effects of age, body weight, or gender on the systemic exposure of alpelisib that would require PIQRAY dose adjustment.

#### *Race/Ethnicity*

Population PK analyses and PK analysis from a single agent study in Japanese cancer patients showed that there are no clinically relevant effects of ethnicity on the systemic exposure of PIQRAY.

Non-compartmental PK parameters after single and multiple daily doses of PIQRAY for Japanese patients were very similar to those reported in the Caucasian population.

## **5.3 Preclinical Safety Data**

### Cardiovascular safety pharmacology

In an *in vitro* hERG test, (where functionality of the human cardiac hERG channel heterologously expressed in HEK293 cells *in vitro* is assessed), an IC<sub>50</sub> of 9.4 µM (4.2 µg/ml) was found. No relevant electrophysiological effect was seen in dogs in several studies, up to single doses of 180 mg/kg *in vivo*. An *in vivo* telemetry study in dogs showed an elevated blood pressure, starting at exposure lower than the exposure in humans, at the highest recommended dose of 300 mg/day.

### **Genotoxicity**

Alpelisib was not mutagenic in an *in vitro* bacterial reverse mutation (Ames) assay, or aneugenic or clastogenic in human cell micronucleus and chromosome aberration tests *in vitro*. Alpelisib was not genotoxic in an *in vivo* rat micronucleus test.

### **Carcinogenicity**

Alpelisib was not carcinogenic in a 2-year carcinogenicity study conducted in rats when administered by daily oral gavage at doses up to 4 mg/kg (approximately 0.2 times the clinical exposure in patients at the highest recommended dose of 300 mg/day based on AUC).

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of Excipients**

PIQRAY tablets contain the following inactive ingredients: microcrystalline cellulose, mannitol, sodium starch glycolate, hypromellose, magnesium stearate (vegetable source), macrogol, iron oxide red CI77491, iron oxide black CI77499, titanium dioxide (E171), and purified talc.

### **6.2 Incompatibilities**

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

### **6.3 Shelf life**

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

### **6.4 Special precautions for Storage**

Store in the original package in order to protect from moisture. Keep out of reach of children.

### **6.5 Nature and contents of the container**

PIQRAY tablets are supplied in PVC/PCTFE (polyvinylchloride/polychlorotrifluoroethylene) or PA/Al/PVC (polyamide/aluminium/polyvinylchloride)/aluminium laminate blister packs.

#### **PIQRAY 50 mg and PIQRAY 200 mg film-coated tablets**

14 day\* or 28 day calendar packs containing 28 film-coated tablets (fourteen 50 mg and fourteen 200 mg) or 56 film-coated tablets (twenty-eight 50 mg and twenty-eight 200 mg).

#### **PIQRAY 150 mg film-coated tablets**

14 day\* or 28 day calendar packs containing 28 or 56 film-coated tablets.

#### **PIQRAY 200 mg film-coated tablets**

14 day\* or 28 day calendar packs containing 14 or 28 film-coated tablets.

\*Not all pack sizes are supplied.

### **6.6 Special precautions for disposal**

Any unused product should not be disposed of in household waste or wastewater. Return it to a pharmacist for safe disposal.

## 6.7 Physicochemical properties


Chemical name (IUPAC): (2*S*)-*N*<sup>1</sup>-{4-Methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl} pyrrolidine-1,2-dicarboxamide

Molecular formula: C<sub>19</sub>H<sub>22</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S

Relative molecular mass: 441.47

Alpelisib is a white to almost white powder at room temperature. It is sparingly soluble in methanol, acetone, and absolute ethanol; it is insoluble/practically insoluble in water, and demonstrates pH-dependent aqueous solubility. Alpelisib is most soluble at pH 1 and has two experimentally determined dissociation constants with pKa values of 3.3 and 9.4. The pH of a 1.0 % (m/v) solution of alpelisib in water/ethanol (50:50 v/v) is approximately 6.2. In an n-octanol/pH 6.8 buffer system, alpelisib has a log D of 2.8. Alpelisib is optically active.

## Chemical structure



## Chemical Abstracts Service (CAS) number

1217486-61-7

## 7. MEDICINE SCHEDULE (POISONS STANDARD)

## Schedule 4 – Prescription Only Medicine

## 8. SPONSOR

NOVARTIS Pharmaceuticals Australia Pty Limited

ABN 18 004 244 160

54 Waterloo Road

Macquarie Park NSW 2113

Telephone 1 800 671 203

Web site: [www.novartis.com.au](http://www.novartis.com.au)

® = Registered Trademark

## 9. DATE OF FIRST APPROVAL

20 March 2020

## 10 DATE OF REVISION

4 December 2025

### Summary table of changes

Section changed	Summary of new information
All	Editorial updates

4.4	Quantitative data updates to reflect the final SOLAR-1 safety data in the hyperglycaemia and diarrhoea sections
4.5	CYP3A4, CYP2C8, CYP2C9, CYP2C19 and CYP2B6 substrates section – correction from increase to decrease of AUC by 11.2%
4.8	Quantitative data updates throughout section to reflect the final SOLAR-1 safety data along with changes to reported ADR frequency of hypokalaemia, ketoacidosis and hypertension in the PIQRAY + Fulvestrant arm (Table 7)
5.1	Correction to mutation assay results used to identify PIK3CA mutation in SOLAR-1 patients
5.3	Revision to carcinogenic text based on findings of rat study

---

Internal document code

Piq041225i based on CDS dated 30 July 2024